ACS Pharmacology & Translational Science launched February 14, 2018, and on May 9, 2018, published its first two peer-reviewed articles as Articles ASAP (As Soon As Publishable): Stabilization of Cyclin-Dependent Kinase 4 by Methionyl-tRNA Synthetase in p16INK4a-Negative Cancer ACS Pharmacol. Transl. Sci., Article ASAP DOI: 10.1021/acsptsci.8b00001 Molecular Signature for Receptor Engagement in the Metabolic Peptide […]
ACS Pharmacology & Translational Science launched February 14, 2018, and on May 9, 2018, published its first two peer-reviewed articles as Articles ASAP (As Soon As Publishable):
Stabilization of Cyclin-Dependent Kinase 4 by Methionyl-tRNA Synthetase in p16INK4a-Negative Cancer
ACS Pharmacol. Transl. Sci., Article ASAP
DOI: 10.1021/acsptsci.8b00001
Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin
ACS Pharmacol. Transl. Sci., Article ASAP
DOI: 10.1021/acsptsci.8b00002
These articles are free to read courtesy of ACS Publications. Both articles come from teams of researchers who are collaborating across disciplines and across continents to make discoveries that advance therapeutic intervention.
“I am excited by the publication of the first papers in ACS Pharmacology & Translational Science. In distinct ways, each provides an important example of how the application of interdisciplinary research can advance understanding of complex biological systems to provide a translational path for future therapeutic intervention,” wrote Editor-in-Chief Patrick Sexton in his May 9, 2018, Editorial “ Advancing Translational Understanding for Cancer and Obesity Therapy.”
Stabilization of Cyclin-Dependent Kinase 4 by Methionyl-tRNA Synthetase in p16 INK4a-Negative Cancer
“This research first unveils an unexpected functional connection between the two key enzymes, namely, methionyl-tRNA synthetase (MRS) for translation and CDK4 for cell cycle control,” Kim said. “This finding also suggests the cancer-promoting interaction between these two enzymes as a new therapeutic point to control cancer. The pathological connection between MRS and CDK4 in cancer was validated in clinical analysis and the therapeutic potential of the MRS-CDK4 interaction was also shown by chemical inhibitors.“
Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin
“The pancreatic peptide hormone amylin has many metabolic benefits, making targeting this system an attractive prospect for treating diabetes and obesity,” Hay said. “Our study is the first comprehensive analysis of how this long peptide engages its complex dimeric receptors, which now maps a path forward for novel amylin mimetic development. We are enthusiastic that this work will provide a valuable resource for others working with amylin and related class B peptide G protein-coupled receptor systems.”
Read “Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin.”
Why ACS Pharmacology & Translational Science?
“Why yet another journal, and why is ACS entering this space,” asked Editor-in-Chief Patrick Sexton in another May 9, 2018, Editorial “Introducing ACS Pharmacology & Translational Science.”
“The latter is easy: chemistry has forever been the foundation of new medicines and the intersection with pharmacology and the need to translate chemical discoveries into new medicines a fundamental axiom of most biological, and all medicinal chemistry programs,” Sexton explained. “Moreover, one needs only to look at recent awardees of the Nobel Prize in Chemistry to understand the fundamental relationship between chemistry and biology. The specific launching of ACS Pharmacology & Translational Science also recognizes a gap in publishing opportunities for authors bringing together interdisciplinary sciences and integrating molecular and biological studies to improve the translational relevance of their research.”
The lead authors of the journal’s first two peer-reviewed articles concur with the need for a major journal focusing on pharmacology and translational research supported by a leading publisher, and they were excited to be the first to publish in ACS Pharmacology & Translational Science.
“ACS Pharmacology & Translational Science provides a perfect place for our research that includes comprehensive data on the fundamental and chemical biology nature of our research question in conjunction with translational research,” said Dr. Sunghoon Kim, lead author of the journal’s first published article.
“The recent launch of the journal ACS Pharmacology & Translational Science gave the perfect opportunity for us to showcase our work,” said Dr. Debbie Hay, lead author of the journal’s second published article. “ACS journals are well-respected and the addition of a pharmacology journal to the portfolio is a significant development, which we are very pleased to have been able to take advantage of.”
How to Read ACS Pharmacology & Translational Science
These first two articles and others published as Articles ASAP (As Soon As Publishable) prior to publication of Volume 1, Issue 1, of ACS Pharmacology & Translational Science are free to read courtesy of ACS Publications. When it publishes later this year, Volume 1, Issue 1, will also be free to read.
Institutional subscribers to ACS All Publications, All Access, and token packages have access to all ACS Pharmacology & Translational Science. We encourage librarians at subscribing institutions to add ACS Pharmacology & Translational Science to their link resolvers using ISSN 2575-9108 and https://pubs.acs.org/journal/aptsfn. You can also email your ACS Publications sales representative with any subscription questions related to this new journal at acspusbssales@acs.org.
